For research use only. Not for therapeutic Use.
VU6007477（Cat No.:I038176）is a selective allosteric modulator of the metabotropic glutamate receptor 4 (mGluR4), a G-protein-coupled receptor involved in regulating neurotransmitter release and synaptic transmission in the brain. By modulating mGluR4, VU6007477 has been investigated for its potential therapeutic effects in neuropsychiatric disorders such as Parkinson’s disease, schizophrenia, and anxiety. It may help to reduce excitatory neurotransmission and balance glutamate activity, which can be dysregulated in various neurological conditions. Preclinical studies suggest that VU6007477 may offer neuroprotective and anti-inflammatory benefits, though further research is required to evaluate its safety and efficacy in clinical settings.
| Catalog Number | I038176 |
| CAS Number | 2220141-46-6 |
| Synonyms | VU6007477; VU-6007477; VU 6007477 |
| Molecular Formula | C24H26N6O2 |
| Purity | 98% |
| Solubility | Soluble in DMSO |
| Appearance | Solid powder |
| Storage | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
| IUPAC Name | 1-methyl-4-[[6-(1-methylpyrazol-4-yl)pyridin-3-yl]methyl]-N-(oxan-4-yl)pyrrolo[2,3-b]pyridine-6-carboxamide |
| InChI | InChI=1S/C24H26N6O2/c1-29-8-5-20-17(11-16-3-4-21(25-13-16)18-14-26-30(2)15-18)12-22(28-23(20)29)24(31)27-19-6-9-32-10-7-19/h3-5,8,12-15,19H,6-7,9-11H2,1-2H3,(H,27,31) |
| InChIKey | OYSPYZFYHUIBOS-UHFFFAOYSA-N |
| SMILES | CN1C=CC2=C1N=C(C=C2CC3=CN=C(C=C3)C4=CN(N=C4)C)C(=O)NC5CCOCC5 |
| Reference | VU6007477, a Novel M1 PAM Based on a Pyrrolo[2,3-b]pyridine Carboxamide Core Devoid of Cholinergic Adverse Events |
